Beyond the Numbers:
Breaking Down Misconceptions in Hypoparathyroidism

by Dr Zaki Hassan-Smith
Honorary Consultant Endocrinologist at University Hospitals Birmingham NHS Foundation Trust and Clinical Associate Professor at Aston University

Hypoparathyroidism (hypopara) is a rare endocrine condition characterised by insufficient levels of parathyroid hormone (PTH) in the body.[1] For some people with hypopara, their symptoms can be well managed. For others however, managing the condition can be very challenging, mainly due to its broad and indistinct symptoms, the close surveillance of calcium levels required, and the balancing act of minimising the short-term impact with the long-term complications of disease.

While the metrics of hypopara – namely a patient's blood levels of calcium, phosphate and vitamin D – remain fundamental to preventing acute complications. As well as the measurements of urine excretion of calcium and the role in preventing the risk of renal complications, such as kidney stones and chronic kidney disease, the challenges of hypopara extend further than these numerical parameters. The unpredictable and often debilitating symptoms can significantly affect quality of life, contributing to a complex clinical picture, and misconceptions around the severe impact of symptoms, psychological burden, and long-term complications persist. We now need a more nuanced understanding of hypopara, that goes beyond the numbers, and looks at the realities of the condition.

The Limitations of a Numbers-Only Approach

As clinicians, we naturally gravitate towards measurable outcomes. In endocrinology practice, this typically translates to a focus on regulating serum calcium and phosphate levels in the blood, to prevent hospitalisation and acute complications. Maintaining this focus is critical – it helps maintain short-term stability for the patient, while reducing healthcare system burden.

However, insights from a recent survey of individuals with hypopara have highlighted challenges with the current approach. Fewer than half of patients surveyed (44.1%) reported being satisfied with their medication regimen, with the leading cause of dissatisfaction being concerns around the long-term side effects (69.3%).[2] By prioritising biochemical targets, are we at risk of overlooking some of the more nuanced, longer-term challenges that define living with hypopara?

Addressing Misconceptions Around Long-Term Consequences to Improve Outcomes

While regulating serum calcium and phosphate levels in the blood may reduce hospital admissions and avoid severe, acute symptoms such as cramps and seizures, it is a misconception to assume all patients with stable readings are adequately controlled. Clinicians must remain vigilant about the potential long-term complications of hypopara that can emerge over time, which include, but are not limited to:

- **Renal complications:** Kidney-related complications related to long-term calcium supplementation are a well-understood challenge of hypopara management. While some patients are knowledgeable about their condition, more can be done to ensure people living with hypopara and their families or carers understand the risk of longer-term renal complications such as chronic kidney disease, nephrolithiasis and nephrocalcinosis.[3]
- **Cardiovascular risk:** Although linked to renal risks, this one may not be front of mind for every clinician treating hypopara. Patients with chronic hypopara, particularly women, face elevated cardiovascular disease risk that may be associated with chronic imbalances in calcium and phosphate levels.[4]
- **Bone health:** Another often overlooked long-term complication, bone quality can become compromised in chronic hypopara due to the absence or inadequate levels of PTH.[5]

Evolving management practices that include comprehensive long-term care strategies are required to ensure physicians can keep patients out of hospital, whilst minimising the complications related to chronic hypopara.

Acknowledging the Psychological Impact of Hypoparathyroidism

As with many chronic diseases, hypopara can have a significant impact on quality of life. When a patient's calcium and phosphorus levels are within range and stable, but the patient continues to feel unwell, we must ask – have we truly achieved our treatment aims?

In endocrinology, where we are typically focused on metrics-based, 'fixable' parameters, non-physical symptoms often pose a challenge. Since 81% of people with hypopara also experience anxiety and 62% experience feelings of depression or sadness, it is essential to acknowledge that psychological manifestations are central to the disease experience and must be brought to the forefront of clinical care.[6] I would highlight the following approaches:

1. **Patient empowerment:** Early in the diagnosis process, it's important to help patients understand the chronic nature of their condition. Emphasise that management will require ongoing adjustments and that symptoms may fluctuate over time. Encourage education on the condition itself, including potential side effects and symptoms such as hypocalcaemia. Encourage self-advocacy, while highlighting the availability of wider support such as specialist nursing.
2. **Community support:** Encourage patients to connect with patient organisations, local charities or patient-first outreach programmes. Parathyroid UK is a well-established national-level group specifically for people with parathyroid conditions and can provide guidance, both in-person and online, that can help with the psychological aspects of the condition.
3. **Recognising and addressing psychological symptoms:** Acknowledge that psychological symptoms, while difficult to quantify, represent core manifestations of the condition rather than secondary concerns. Patients often report that it is powerful to discuss their symptoms with clinicians who listen to them and acknowledge the impact that their symptoms are having. Practise active listening and record when patients describe changes in cognitive function, mood or energy levels that differ from their 'normal'.
4. **Long-term monitoring and plans:** Approach management of hypopara holistically, with a focus on stability from both a physiological and psychological perspective. Ensure the person living with hypopara knows that achieving stability requires time and patience.

The Role of Data and Best Practice-Sharing to Improve Understanding

Finally, as we manage this complex condition, systematic collection and analysis of data, including patient-reported outcomes, will become crucial for improving understanding and advancing quality of care. This data will help build a solid evidence base, identify management gaps and guide innovation. To do this, I would encourage endocrinologists and other clinicians involved in the management of the condition, to do the following:

- Document and share best-practice with colleagues in your Trust and at regional and national meetings. From my experience, I know lots of excellent work is being done by clinicians across the UK – but more could be done to access, share and harness existing national data and learnings.
- Contribute to registries, data collections, and surveys to strengthen the evidence base and advance understanding in the field.
- Implement quality of life assessment tools to collect patient-reported data.

By adopting a comprehensive approach that recognises the short and long-term physiological and psychological aspects of hypopara, we can break down misconceptions around this rare and difficult-to-treat condition, and look beyond the numbers to ultimately bring better outcomes for people living with hypopara.

Seeds of Change is a disease awareness initiative developed and funded by Ascendis Pharma UK Limited and supported by Parathyroid UK and Society for Endocrinology.

[1] Bollerslev et al. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015 Aug;173(2):G1-20.

[2] Glenister L et al 2025. Burden of Managing Hypoparathyroidism Medication Regimes: a patient survey. Presented at Society for Endocrinology BES 2025, Harrogate, UK. Endocrine Abstracts 109 82.

[3] Mitchell DM et al. Long-Term Follow-Up of Patients with Hypoparathyroidism. The Journal of Clinical Endocrinology & Metabolism. 2013 Dec; 97(12): 4507-14.

[4] Mannstadt et al. The Journal of Clinical Endocrinology and Metabolism: Increased risk of Cardiovascular Diseases in Patients with Chronic Hypoparathyroidism in Sweden. 2015 Apr. 10.1210/clinem/dgaf257

[5] Silva BC. Skeletal and nonskeletal consequences of hypoparathyroidism. Archives of Endocrinology and Metabolism. 2022;66(5):642-50.

[6] Brod M et al. Living with hypoparathyroidism: development of the Hypoparathyroidism Patient Experience Scale-Impact (HPES-Impact). Qual Life Res. 2021. Jan;30(1):277-291, doi: 10.1007/s11136-020-02607-1. Epub 2020 Aug 24. PMID: 32833143; PMCID: PMC7847873.